Example: stock market

Bortezomib For Injection

Found 6 free book(s)
Sr. Drug Generic Name of the Medicine Unit Size MRP ...

Sr. Drug Generic Name of the Medicine Unit Size MRP ...

janaushadhi.gov.in

82 809 Bortezomib Injection 3.5 mg Vial Vial 3188. 00 Anticancer/Oncology 83 819 Capecitabine Tab I.P 500mg 10's 420.0 0 Anticancer/Oncology 84 851 Dacarbazine Injection 200mg VIAL Vial 188.0 0 Anticancer/Oncology 85 853 Daunorubicin HCl Injection 20mg vial Vial 204.0 0 Anticancer/Oncology 86 916 Imatinib mesylate Tablets IP 400mg 10's

  Injection, Bortezomib, Bortezomib injection

DARATUMUMAB WITH BORTEZOMIB AND …

DARATUMUMAB WITH BORTEZOMIB AND …

nssg.oxford-haematology.org.uk

Bortezomib** 1.3 mg/m2 TWICE a week given as SC bolus Days 1,4,8 and 11 Dexamethasone 20mg PO once daily on the day of and day after bortezomib injection Days 2**, 4, 5, 8, 9, 11 and 12 *On day 1, dexamethasone is given as pre-med 1 …

  Injection, Bortezomib, Bortezomib injection

DOSE BANDING TABLES - HSE.ie

DOSE BANDING TABLES - HSE.ie

www.hse.ie

bortezomib subcutaneous injection (version 1) The dose bands used in this table are constructed based on a 2.5mg/ml concentration of bortezomib Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

  Injection, Bortezomib

Prescribing Information | VELCADE® (bortezomib)

Prescribing Information | VELCADE® (bortezomib)

www.velcade.com

VELCADE® (bortezomib) for injection, for subcutaneous or intravenous use Initial U.S. Approval: 2003 -----INDICATIONS AND USAGE----- VELCADE is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma (1.1) treatment of adult patients with mantle cell lymphoma (1.2)

  Information, Prescribing, Injection, Prescribing information, For injection, Bortezomib

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

www.ema.europa.eu

Bortezomib should be administered via subcutaneous injection (1.3 mg/m2 body surface area) twice weekly on days 1, 4, 8 and 11 of each 21-day. For additional information on the dose, schedule and dose adjustments of medicinal products administered with

  Injection, Bortezomib

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

www.ema.europa.eu

VELCADE 1mg powder for solution for injection is administered via intravenous injection in combination with oral melphalan and oral prednisone as shown in Table2. A 6-week period is considered a treatment cycle. In Cycles1-4, VELCADE is administered twice weekly on days1, 4, 8, 11, 22, 25, 29 and 32.

  Product, Summary, Characteristics, Injection, Summary of product characteristics, For injection

Similar queries